Postmastectomy radiotherapy in pN1 breast cancer: Survival outcomes and prognostic factors from a single-institution cohort
PLOS One · 01.06.2026 · 21 (6) · e0341754
DOI: 10.1371/journal.pone.0341754 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 01.06.2026. Verfasst von Raksha M Narasimhan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education, University of Miami Miller School of Medicine, Miami, Florida, United States of America. Hauptthemen laut MEDLINE: Mastectomy, Triple Negative Breast Neoplasms, Breast Neoplasms. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose/Objectives The role of postmastectomy radiotherapy (PMRT) in patients with pathologic N1 (pN1) breast cancer, including triple-negative breast cancer (TNBC), remains controversial in the era of modern systemic therapy. We evaluated the association between PMRT and recurrence-free survival (RFS) and overall survival (OS) and identified prognostic factors in a contemporary single-institution pN1 cohort. Materials/Methods We retrospectively reviewed female patients with pT1-2N1M0 breast cancer treated with mastectomy between 1999 and 2023. RFS and OS were estimated using Kaplan-Meier methods and compared by PMRT status with log-rank testing. Univariable Cox proportional hazards models assessed associations between clinical factors—including tumor laterality, receptor subtype (TNBC vs non-TNBC), nodal burden, and adjuvant therapies—and survival outcomes, with subgroup analyses by PMRT status and receptor subtype.
Results
Fifty-seven patients were included; 22 (38.6%) received PMRT. With a median follow-up of 85 months, PMRT was not associated with improved RFS (median 133 vs 120 months; p = 0.256) or OS (not reached vs 195 months; p = 0.154). Hormone therapy was significantly associated with improved RFS (HR 0.43; p = 0.026) and OS (HR 0.13; p = 0.003), while having 2–3 positive lymph nodes predicted worse RFS (HR 2.86; p = 0.007). No significant differential benefit from PMRT was observed in patients with TNBC or non-TNBC disease.
Conclusions
PMRT was not associated with a survival benefit in this pN1 cohort, including patients with TNBC. Interpretation is limited by modest sample size and statistical power. Outcomes appeared driven by tumor biology, nodal burden, and systemic therapy, supporting individualized PMRT decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medical Education, University of Miami Miller School of Medicine, Miami, Florida, United States of America.
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, United States of America.
- Department of Biostatistics, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, Florida, United States of America.
ORCID-Profile: Raksha M Narasimhan
Zitieren
APA
Narasimhan, R. M., Saini, A. S., Samimi, K., Ogobuiro, I., Zhao, X., Han, S., Takita, C., & Taswell, C. S. (2026). Postmastectomy radiotherapy in pN1 breast cancer: Survival outcomes and prognostic factors from a single-institution cohort. PLOS One, 21(6), e0341754. https://doi.org/10.1371/journal.pone.0341754
Vancouver
Narasimhan RM, Saini AS, Samimi K, Ogobuiro I, Zhao X, Han S, et al. Postmastectomy radiotherapy in pN1 breast cancer: Survival outcomes and prognostic factors from a single-institution cohort. PLOS One. 2026;21(6):e0341754. doi:10.1371/journal.pone.0341754
BibTeX
@article{Narasimhan2026,
author = {Narasimhan, Raksha M and Saini, Aren Singh and Samimi, Kayla and Ogobuiro, Ifeanyichukwu and Zhao, Xuesen and Han, Sunwoo and Takita, Cristiane and Taswell, Crystal S},
title = {Postmastectomy radiotherapy in pN1 breast cancer: Survival outcomes and prognostic factors from a single-institution cohort},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {6},
pages = {e0341754},
doi = {10.1371/journal.pone.0341754}
}
EUVIMED